Abstract
The clinical, radiographic, and histopathologic features of ILD in myositis are similar to idiopathic ILD. Patients with a known diagnosis of inflammatory myopathy require a prompt clinical evaluation and the assessment of myositis-associated autoantibodies. Patients possessing autoantibodies associated with ILD or those with any pulmonary symptoms should have pulmonary functions test and high resolution CT (HRCT) scanning of their lungs. Despite the lack of placebocontrolled trials, systemic glucocorticoids are considered the mainstay of initial treatment of myositisassociated ILD. Glucocorticoid-sparing agents are often started concomitantly with glucocorticoids, particularly in patients with severe disease. The first-line conventional immunosuppressive drugs include either mycophenolate mofetil or azathioprine. If these agents fail or if the features are more severe or rapidly progressive, then more aggressive immunosuppressive or immunomodulatory therapy including cyclophosphamide, tacrolimus or cyclosporine, or rituximab should be considered. Further investigations are required to assess the role of novel therapies in the treatment of myositis-associated ILD.
Keywords: Dermatomyositis, idiopathic inflammatory myopathy, interstitial lung disease, myositis, polymyositis, pulmonary fibrosis, treatment.
Current Respiratory Medicine Reviews
Title:Interstitial Lung Disease in Myositis
Volume: 11 Issue: 2
Author(s): Siamak Moghadam-Kia, Chester V. Oddis and Rohit Aggarwal
Affiliation:
Keywords: Dermatomyositis, idiopathic inflammatory myopathy, interstitial lung disease, myositis, polymyositis, pulmonary fibrosis, treatment.
Abstract: The clinical, radiographic, and histopathologic features of ILD in myositis are similar to idiopathic ILD. Patients with a known diagnosis of inflammatory myopathy require a prompt clinical evaluation and the assessment of myositis-associated autoantibodies. Patients possessing autoantibodies associated with ILD or those with any pulmonary symptoms should have pulmonary functions test and high resolution CT (HRCT) scanning of their lungs. Despite the lack of placebocontrolled trials, systemic glucocorticoids are considered the mainstay of initial treatment of myositisassociated ILD. Glucocorticoid-sparing agents are often started concomitantly with glucocorticoids, particularly in patients with severe disease. The first-line conventional immunosuppressive drugs include either mycophenolate mofetil or azathioprine. If these agents fail or if the features are more severe or rapidly progressive, then more aggressive immunosuppressive or immunomodulatory therapy including cyclophosphamide, tacrolimus or cyclosporine, or rituximab should be considered. Further investigations are required to assess the role of novel therapies in the treatment of myositis-associated ILD.
Export Options
About this article
Cite this article as:
Moghadam-Kia Siamak, Oddis V. Chester and Aggarwal Rohit, Interstitial Lung Disease in Myositis, Current Respiratory Medicine Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573398X11666150619184220
DOI https://dx.doi.org/10.2174/1573398X11666150619184220 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selective Elevation of Circulating CCL2/MCP1 Levels in Patients with Longstanding Post-vaccinal Macrophagic Myofasciitis and ASIA
Current Medicinal Chemistry Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Snake Venom Prothrombin Activators Similar to Blood Coagulation Factor Xa
Current Drug Targets - Cardiovascular & Hematological Disorders The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Interstitial Lung Disease in Systemic Lupus Erythematosus, Sjogren’s Syndrome, and Mixed Connective Tissue Disease
Current Respiratory Medicine Reviews Disaggregating Chaperones: An Unfolding Story
Current Protein & Peptide Science Laser Modified Phenothiazines and Hydantoins: Photo-products Characterisation and Application on Animal Eyes Pseudo-tumours
Letters in Drug Design & Discovery Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
Current Rheumatology Reviews Objective Biomarkers or Symptom Scores for the Classification of Fibromyalgia Syndrome?
Current Rheumatology Reviews Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It
Current HIV Research Treatment of Interstitial Lung Disease Associated with Polymyositis- Dermatomyositis: An Update
Current Respiratory Medicine Reviews Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design Biological Function and Medicinal Research Significance of G-Quadruplex Interactive Proteins
Current Topics in Medicinal Chemistry A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus
Current Pharmaceutical Design Antineutrophil Cytoplasmic Antibody in Lupus Nephritis: Correlation with Clinicopathological Characteristics and Disease Activity
Current Rheumatology Reviews Neurosarcoidosis
Current Neuropharmacology Recent Synthetic Strategies for Monocyclic Azole Nucleus and Its Role in Drug Discovery and Development
Current Organic Synthesis Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Genetic and Non-Genetic Determinants of the Pharmacological Activity of Statins
Current Drug Metabolism